{"id":684723,"date":"2024-01-16T08:56:01","date_gmt":"2024-01-16T08:56:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=684723"},"modified":"2024-01-16T08:56:01","modified_gmt":"2024-01-16T08:56:01","slug":"sepsis-market-and-epidemiology-2032-treatment-market-therapies-companies-fda-approvals-epidemiology-and-forecast-by-delveinsight-vivacelle-bio-inotrem-sa-enlivex-therapeutics","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/sepsis-market-and-epidemiology-2032-treatment-market-therapies-companies-fda-approvals-epidemiology-and-forecast-by-delveinsight-vivacelle-bio-inotrem-sa-enlivex-therapeutics_684723.html","title":{"rendered":"Sepsis Market and Epidemiology 2032: Treatment Market, Therapies, Companies, FDA Approvals, Epidemiology and Forecast by DelveInsight | Vivacelle Bio, Inotrem SA, Enlivex Therapeutics"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1705321330.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Sepsis Market and Epidemiology 2032: Treatment Market, Therapies, Companies, FDA Approvals, Epidemiology and Forecast by DelveInsight | Vivacelle Bio, Inotrem SA, Enlivex Therapeutics\" src=\"https:\/\/www.abnewswire.com\/uploads\/1705321330.jpeg\" alt=\"Sepsis Market and Epidemiology 2032: Treatment Market, Therapies, Companies, FDA Approvals, Epidemiology and Forecast by DelveInsight | Vivacelle Bio, Inotrem SA, Enlivex Therapeutics\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">\u201cSepsis Market Insights, Epidemiology, and Market Forecast-2032\u2033 report offers an in-depth understanding of the Sepsis, historical and forecasted epidemiology as well as the Sepsis market trends in the 7MM.<\/div>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s <strong>&ldquo;Sepsis Market Insights, Epidemiology, and Market Forecast-2032&Prime;<\/strong> report offers an in-depth understanding of the Sepsis, historical and forecasted epidemiology as well as the Sepsis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>To Know in detail about the Sepsis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/sepsis-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Sepsis Market Forecast<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Some of the key facts of the Sepsis Market Report:&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The Sepsis market size was valued approximately <strong>USD 2,807 million in 2022<\/strong> and is anticipated to grow with a significant CAGR during the study period (2019-2032)<\/li>\n<li>In May 2022, <strong>Phathom Pharmaceuticals, Inc.<\/strong> obtained approval from the United States Food and Drug Administration (FDA) for <strong>VOQUEZNA TRIPLE PAK (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets)<\/strong> and <strong>VOQUEZNA DUAL PAK (vonoprazan tablets, amoxicillin capsules)<\/strong> to treat Helicobacter pylori (H. pylori) infection in adults. The New Drug Applications for these products were earlier designated as qualified infectious disease products (QIDP).<\/li>\n<li><strong>In May 2022, The Sepsis Alliance<\/strong> introduced the Sepsis Innovation Collaborative (SIC), aiming to advance early diagnosis, improve antimicrobial therapies, develop host-modifying agents, and more in the fight against sepsis. As one of the pioneering public-private collaborative communities, SIC includes members such as Beckman Coulter, Merck, BioAegis Therapeutics, Roche, and other companies.<\/li>\n<li>In 2022, the 7MM documented <strong>3,543,995 cases<\/strong> of sepsis, and projections indicate an anticipated increase by 2032. Among these cases, the United States held the largest share, contributing <strong>55%<\/strong> to the overall sepsis population, amounting to <strong>1,938,855 cases<\/strong> in 2022.<\/li>\n<li>In 2022, the combined total of sepsis cases in the EU4 and the UK reached <strong>1,210,184,<\/strong> and there is an anticipated increase by 2032. Among the EU countries, Germany had the highest share in the sepsis population, recording<strong> 322,020<\/strong> cases in 2022.<\/li>\n<li>In Japan, there were<strong> 394,956 new cases<\/strong> of sepsis reported. The epidemiological data reveals that the incidence in Japan constituted 11% of the overall patient pool in the 7MM in 2022.<\/li>\n<li><strong>Key Sepsis Companies:<\/strong> Vivacelle Bio, Inotrem SA, Enlivex Therapeutics, and others<\/li>\n<li><strong>Key Sepsis Therapies:<\/strong> VBI-S, Nangibotide, Allocetra, and others<\/li>\n<li>The Sepsis epidemiology based on gender analyzed that in the 7MM, the majority of patient pool were males as compared to females whereas in the US female population dominated the Sepsis incident pool<\/li>\n<li>The Sepsis market is expected to surge due to the disease&#8217;s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Sepsis pipeline products will significantly revolutionize the Sepsis market dynamics.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Sepsis Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Sepsis is a severe and potentially life-threatening condition that occurs when the body&#8217;s response to an infection leads to systemic inflammation. The immune system&#8217;s response to infection can sometimes become overactive, triggering widespread inflammation that can result in organ dysfunction or failure.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Get a Free sample for the Sepsis Market Forecast, Size &amp; Share Analysis Report:&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/sepsis-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">https:\/\/www.delveinsight.com\/report-store\/sepsis-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Sepsis Epidemiology<\/strong><\/p>\n<p style=\"text-align: justify;\">The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Sepsis Epidemiology Segmentation:<\/strong><\/p>\n<p style=\"text-align: justify;\">The Sepsis market report proffers epidemiological analysis for the study period 2019&ndash;2032 in the 7MM segmented into:<\/p>\n<ul style=\"text-align: justify;\">\n<li>Total Prevalence of Sepsis<\/li>\n<li>Prevalent Cases of Sepsis by severity<\/li>\n<li>Gender-specific Prevalence of Sepsis<\/li>\n<li>Diagnosed Cases of Episodic and Chronic Sepsis<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Download the report to understand which factors are driving Sepsis epidemiology trends @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/sepsis-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Sepsis Epidemiology Forecast<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Sepsis Drugs Uptake and Pipeline Development Activities<\/strong><\/p>\n<p style=\"text-align: justify;\">The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Sepsis market or expected to get launched during the study period. The analysis covers Sepsis market uptake by drugs, patient uptake by therapies, and sales of each drug.&nbsp;<\/p>\n<p style=\"text-align: justify;\">Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.<\/p>\n<p style=\"text-align: justify;\">The report also covers the Sepsis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Sepsis Therapies and Key Companies<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>VBI-S:<\/strong> Vivacelle Bio<\/li>\n<li><strong>Nangibotide:<\/strong> Inotrem SA<\/li>\n<li><strong>Allocetra:<\/strong> Enlivex Therapeutics<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Discover more about therapies set to grab major Sepsis market share @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/sepsis-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Sepsis Treatment Landscape<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Sepsis Market Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Study Period: 2019&ndash;2032<\/strong><\/li>\n<li><strong>Coverage:<\/strong> 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]<\/li>\n<li><strong>Key Sepsis Companies:<\/strong> Vivacelle Bio, Inotrem SA, Enlivex Therapeutics, and others<\/li>\n<li><strong>Key Sepsis Therapies:<\/strong> VBI-S, Nangibotide, Allocetra, and others<\/li>\n<li><strong>Sepsis Therapeutic Assessment:<\/strong> Sepsis current marketed and Sepsis emerging therapies<\/li>\n<li><strong>Sepsis Market Dynamics:<\/strong> Sepsis market drivers and Sepsis market barriers&nbsp;<\/li>\n<li><strong>Competitive Intelligence Analysis:<\/strong> SWOT analysis, PESTLE analysis, Porter&rsquo;s five forces, BCG Matrix, Market entry strategies<\/li>\n<li><strong>Sepsis Unmet Needs, KOL&rsquo;s views, Analyst&rsquo;s views, Sepsis Market Access and Reimbursement&nbsp;<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>To know more about Sepsis companies working in the treatment market, visit @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/sepsis-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Sepsis Clinical Trials and Therapeutic Assessment<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Sepsis Market Report Introduction<\/p>\n<p style=\"text-align: justify;\">2. Executive Summary for Sepsis<\/p>\n<p style=\"text-align: justify;\">3. SWOT analysis of Sepsis<\/p>\n<p style=\"text-align: justify;\">4. Sepsis Patient Share (%) Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">5. Sepsis Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">6. Sepsis Disease Background and Overview<\/p>\n<p style=\"text-align: justify;\">7. Sepsis Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\">8. Country-Specific Patient Population of Sepsis&nbsp;<\/p>\n<p style=\"text-align: justify;\">9. Sepsis Current Treatment and Medical Practices<\/p>\n<p style=\"text-align: justify;\">10. Sepsis Unmet Needs<\/p>\n<p style=\"text-align: justify;\">11. Sepsis Emerging Therapies<\/p>\n<p style=\"text-align: justify;\">12. Sepsis Market Outlook<\/p>\n<p style=\"text-align: justify;\">13. Country-Wise Sepsis Market Analysis (2019&ndash;2032)<\/p>\n<p style=\"text-align: justify;\">14. Sepsis Market Access and Reimbursement of Therapies<\/p>\n<p style=\"text-align: justify;\">15. Sepsis Market Drivers<\/p>\n<p style=\"text-align: justify;\">16. Sepsis Market Barriers<\/p>\n<p style=\"text-align: justify;\">17.&nbsp; Sepsis Appendix<\/p>\n<p style=\"text-align: justify;\">18. Sepsis Report Methodology<\/p>\n<p style=\"text-align: justify;\">19. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\">20. Disclaimer<\/p>\n<p style=\"text-align: justify;\">21. About DelveInsight<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About DelveInsight&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.<\/p>\n<p style=\"text-align: justify;\">It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56433.html\" rel=\"nofollow\">DelveInsight<\/a><br \/><strong>Contact Person:<\/strong> Gaurav Bora<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=sepsis-market-and-epidemiology-2032-treatment-market-therapies-companies-fda-approvals-epidemiology-and-forecast-by-delveinsight-vivacelle-bio-inotrem-sa-enlivex-therapeutics\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV 89107<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/consulting\/due-diligence-services\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/consulting\/due-diligence-services<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/consulting\/due-diligence-services\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=sepsis-market-and-epidemiology-2032-treatment-market-therapies-companies-fda-approvals-epidemiology-and-forecast-by-delveinsight-vivacelle-bio-inotrem-sa-enlivex-therapeutics\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u201cSepsis Market Insights, Epidemiology, and Market Forecast-2032\u2033 report offers an in-depth understanding of the Sepsis, historical and forecasted epidemiology as well as the Sepsis market trends in the 7MM. DelveInsight&rsquo;s &ldquo;Sepsis Market Insights, Epidemiology, and Market Forecast-2032&Prime; report offers an &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/sepsis-market-and-epidemiology-2032-treatment-market-therapies-companies-fda-approvals-epidemiology-and-forecast-by-delveinsight-vivacelle-bio-inotrem-sa-enlivex-therapeutics_684723.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-684723","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/684723","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=684723"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/684723\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=684723"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=684723"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=684723"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}